MMP9 and Friedreich ataxia: In vitro therapeutic results revealed FA-CD-PLLD/DOC/MMP-9 showed the better therapeutic effect on HNE-1 cells compared to non-targeting CD-PLLD/DOC/MMP-9 through flow apoptosis and cell invasion assays, which benefited from the molecular targeting of FA.